DamianoRondelliMD

Hematologic Oncology

Michael Reese Professor and Chief, Division of Hematology/Oncology - Director, Blood, Marrow and Cellular Therapy, Department of Medicine, University of Illinois College of Medicine

Join to view full profile

Dr. Rondelli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rondelli's full profile

Already have an account?

Office
1740 W Taylor St
Dept 3462
Chicago, IL 60612
Phone+1 312-704-2885

Fax+1 312-704-2737

Education & Training

University of BolognaClass of 1990

Certifications & Licensure

IL State Medical License 2002 - 2026

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Chicago Magazine: Top Doctors Castle Connolly, 2014

Clinical Trials

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis Start of enrollment: 2007 Aug 01
Completed
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
Familial Myeloproliferative Disorders Start of enrollment: 2008 Mar 01
Completed
Research Tissue Bank Start of enrollment: 2007 Sep 01
Completed
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies Start of enrollment: 2009 Sep 01
Completed
Not Applicable
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Contact, Principal Investigator
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies Start of enrollment: 2000 Feb 01
Completed
Not Applicable
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) Start of enrollment: 2011 Nov 11
Recruiting
Phase 1, Phase 2
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis Start of enrollment: 2013 Nov 01
Terminated
Phase 2
SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD Start of enrollment: 2014 Apr 10
Terminated
Phase 2
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease Start of enrollment: 2017 Mar 20
Recruiting
Phase 2
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes Start of enrollment: 2017 Apr 24
Recruiting
Phase 2
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) Start of enrollment: 2020 Jan 27
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

495 citations
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Haydar Frangoul, David Altshuler, M Domenica Cappellini, Yi-Shan Chen, Jennifer Domm
The New England Journal of Medicine. 2021-01-21
39 citations
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres
Mohsen Alzahrani, Moussab Damlaj, Neal Jeffries, Bader Alahmari, Avani Singh
British Journal of Haematology. 2021-02-03
202 citations
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
Kröger N, J. H. Deeg, Eduardo Olavarria, Dietger Niederwieser, Almalina Bacigalupo
Leukemia. 2015-11-01

Abstracts/Posters

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Damiano Rondelli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant
Damiano Rondelli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Un...
Damiano Rondelli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Monitoring of Stored Hematopoietic Stem/Progenitor Graft Stability Program in a Single Institute
Damiano Rondelli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients ...
Damiano Rondelli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Press Mentions

Researchers Explore Gene Editing as a New Cure for Blood DisordersFebruary 9th, 2021
UIC Researcher Awarded $10.15M to Develop Antibody-Based Dry Eye TreatmentFebruary 8th, 2021
UChicago Medicine to Use Lottery System to Distribute Vaccines • How Getting COVID Changed These Health Leaders' POV • Lurie, Rush Ink Pediatric PartnershipJanuary 25th, 2021
Join now to see all

Other Languages

Spanish, Italian